Obtaining a high yield of immune cells for cell therapy research and immunotherapy development can be challenging. Current workflows are often sub-optimal; their reliance on the use of serum and feeder cells leaves them prone to variability. In addition, the need for autologous cell sources adds further uncertainty and complexity. This can increase the risk of delays, high costs, and issues with getting approvals from regulatory bodies. Researchers must consider every step of their workflow when optimizing protocols to enhance consistency and performance.

In this Innovation Showcase talk from ISSCR 2023, Drs. Nooshin Tabatabaei-Zavareh and Patrick Brauer from STEMCELL Technologies introduce tools that offer optimal conditions for generating immune cells from alternative cell sources, including cord blood-derived hematopoietic stem & progenitor cells or pluripotent stem cells. Our media and supplements have been developed using defined materials and protocols without the use of serum or feeder cells, facilitating the generation of high-quality cell products required in clinical applications.

As a sponsor of, and participant in, ISSCR’s 2023 Annual Meeting, we share with you our Innovation Showcase presentation at #ISSCR2023. This presentation does not represent an endorsement from or support of the ISSCR.